Skip to Main Content
Services Talent Knowledge
Site Search
Menu

XunChen

She | Her | Hers

Associate

Overview

Biography

Xun focuses her practice on complex commercial litigation in state and federal courts. She represents corporate and individual clients across a variety of industries, including consumer products, industrial products, pharmaceuticals, automotive, and aviation, in products liability cases, class actions, securities litigation, and contract disputes. Her representation has included Fortune 100 and 500 companies in multi-million dollar lawsuits.

Selected Memberships & Affiliations

  • Barclay Damon’s Women’s Forum

Languages

  • Mandarin
Experience

Prior Experience

  • Lynch Daskal Emery LLP, Associate
  • The Sarachek Law Firm, Summer Associate
  • New York State Office of the Attorney General, Law Clerk
     

Selected Honors

  • Best Lawyers: Ones to Watch® in America: Commercial Litigation, 2026; Litigation – Securities, 2026; Mass Tort Litigation/Class Actions – Defendants, 2026; Product Liability Litigation – Defendants, 2024–2026
  • Selected to Super Lawyers New York Metro Rising Stars: Business Litigation, 2024
  • Fordham University School of Law, NAPABA Thomas Tang Moot Court Competition, Regional Best Brief, 2017
  • Fordham University School of Law, Archibald R. Murray Public Service Award, Summa Cum Laude, 2018
     

Featured Media

Alerts

Website Accessibility Lawsuits: Several "Tester" Plaintiffs—Sandra Ford, Z'Leah Liburd, Livingston Bennett, Brandi Major, and Joshua Espinal—Targeting Businesses in Recent Flurry of Lawsuits

Alerts

Year-End Focus for 403(b) Plan Sponsors: Two Critical Document Deadlines and Typical Year-End Compliance Review

Alerts

Second Circuit Reverses Award of Attorney's Fees in Coverage Dispute Between Liability Insurers

Alerts

Federal Court Narrows Scope of Insurers' Privilege Claims in COVID-19 Coverage Litigation

Alerts

AstraZeneca Escalates FARXIGA® Audit Demands: What Pharmacies Need to Know Now

Alerts

Update on the Evolving Guidance for H-1B Entry Restrictions Under September 19 Presidential Proclamation